Epix Pharmaceuticals Explained

Epix Pharmaceuticals Inc (formerly Predix Pharmaceuticals Inc) was a pharmaceutical company based in Lexington, Massachusetts.

Its products included the following agents:

• PRX-00023—5-HT_1A receptor full agonist (later discovered to be an antagonist): for major depression and generalized anxiety disorder
• PRX-03140—5-HT₄ receptor partial agonist: for Alzheimer's disease
• PRX-07034—5-HT₆ receptor antagonist: for obesity and cognitive impairment associated with Alzheimer's disease and schizophrenia
• PRX-08066—5-HT_2B receptor antagonist: for pulmonary hypertension associated with chronic obstructive pulmonary disease

As of July 2009, the company was in the process of asset liquidation due to insufficient funds to stay afloat.^[1]

External links

• EPIX Pharmaceuticals, Inc. web site

Notes and References

1. News: Epix Pharmaceuticals of Lexington is latest biotech to fall to funding crunch . Weisman . Robert . 22 July 2009 . . 23 November 2011.